PMID- 37418107
OWN - NLM
STAT- MEDLINE
DCOM- 20240125
LR  - 20240206
IS  - 1863-4362 (Electronic)
IS  - 0021-1265 (Linking)
VI  - 193
IP  - 1
DP  - 2024 Feb
TI  - Matriptase as a potential biomarker and therapeutic target in newly diagnosed 
      type 2 diabetes mellitus.
PG  - 223-230
LID - 10.1007/s11845-023-03441-3 [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that 
      affects the processing of carbohydrates, proteins, and lipids. In T2DM, metabolic 
      dysregulation occurs through various pathways caused by increased levels of many 
      adipokines and inflammatory chemokines. Impaired insulin-glucose metabolism 
      occurs in tissues. The proteolytic enzyme matriptase is thought to be closely 
      related to glucose metabolism due to its glycolization sites. AIM: Our study 
      aimed to evaluate the correlation between matriptase, a proteolytic enzyme, and 
      metabolic parameters in individuals recently diagnosed with T2DM. We also sought 
      to investigate the potential involvement of matriptase in the development of 
      diabetes. METHODS: We measured all participants' metabolic laboratory parameters, 
      including basic biochemical tests, hemograms, high-sensitivity C-reactive protein 
      (hsCRP), and matriptase levels. RESULTS: Our results showed a significant 
      increase in circulating matriptase levels in individuals with T2DM compared to 
      the control group. Furthermore, individuals with metabolic syndrome had 
      significantly higher matriptase levels than those without in the T2DM and control 
      groups. We also observed that T2DM patients had elevated levels of Homeostatic 
      Model Assessment for Insulin Resistance (HOMA-IR), hsCRP, and matriptase, which 
      displayed a positive correlation. CONCLUSION: Our study is the first to report 
      elevated levels of matriptase in individuals with newly diagnosed T2DM and/or 
      metabolic syndrome. Additionally, we found a significant positive correlation 
      between matriptase levels and metabolic and inflammatory parameters, indicating a 
      potential role for matriptase in the pathogenesis of T2DM and glucose metabolism. 
      Further research on matriptase could lead to its recognition as a novel target 
      for investigation.
CI  - (c) 2023. The Author(s), under exclusive licence to Royal Academy of Medicine in 
      Ireland.
FAU - Demir, Ismail
AU  - Demir I
AUID- ORCID: 0000-0001-7787-1443
AD  - Department of Internal Medicine, Health Sciences University, Izmir, Bozyaka 
      Training and Research Hospital, 35170, Karabaglar, Izmir, Turkey. 
      dr.ismail.demir.36@gmail.com.
FAU - Yilmaz, Ismail
AU  - Yilmaz I
AD  - Faculty of Medicine, Department of Pharmacology and Toxicology, Izmir Katip 
      Celebi University, Izmir, Turkey.
FAU - Horoz, Ersan
AU  - Horoz E
AD  - Faculty of Medicine, Department of Pharmacology and Toxicology, Izmir Katip 
      Celebi University, Izmir, Turkey.
FAU - Calik, Bulent
AU  - Calik B
AD  - Department of General Surgery, Health Sciences University Izmir, Bozyaka Training 
      and Research Hospital, Izmir, Turkey.
FAU - Bilgir, Oktay
AU  - Bilgir O
AD  - Department of Internal Medicine, Health Sciences University, Izmir, Bozyaka 
      Training and Research Hospital, 35170, Karabaglar, Izmir, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20230707
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
RN  - EC 3.4.21.- (matriptase)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - IY9XDZ35W2 (Glucose)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Metabolic Syndrome
MH  - C-Reactive Protein/metabolism
MH  - *Insulin Resistance/physiology
MH  - Glucose
MH  - Serine Endopeptidases/therapeutic use
MH  - Biomarkers
MH  - Blood Glucose/metabolism
OTO - NOTNLM
OT  - Inflammation
OT  - Insulin resistance
OT  - Matriptase
OT  - Metabolic syndrome
OT  - Newly diagnosed type 2 diabetes mellitus
EDAT- 2023/07/07 13:05
MHDA- 2024/01/25 06:43
CRDT- 2023/07/07 11:13
PHST- 2023/06/01 00:00 [received]
PHST- 2023/06/26 00:00 [accepted]
PHST- 2024/01/25 06:43 [medline]
PHST- 2023/07/07 13:05 [pubmed]
PHST- 2023/07/07 11:13 [entrez]
AID - 10.1007/s11845-023-03441-3 [pii]
AID - 10.1007/s11845-023-03441-3 [doi]
PST - ppublish
SO  - Ir J Med Sci. 2024 Feb;193(1):223-230. doi: 10.1007/s11845-023-03441-3. Epub 2023 
      Jul 7.